Mondaq Canada: Food, Drugs, Healthcare, Life Sciences
Norton Rose Fulbright Canada LLP
The Minister of Health refused to list a patent on the Patent Register in respect of a fixed-dose combination product because it did not contain a claim for each medicinal ingredient in the approved product.
Miller Thomson LLP
Organizations engaged in research involving humans are required to have proposed projects reviewed by a research ethics board ("REB").
Norton Rose Fulbright Canada LLP
AstraZeneca Canada Inc. (AstraZeneca) appealed from the decision of Justice Rennie of the Federal Court (reported as AstraZeneca Canada Inc. v. Apotex Inc., 2014 FC 638) holding that AstraZeneca's ‘653 Patent was invalid for lack of demonstrated or soundly predicted utility.
McCarthy Tétrault LLP
In Charlton v. Abbott Laboratories, Ltd., 2015 BCCA 26, the Court of Appeal for British Columbia overturned certification of a class action on behalf of all Canadian consumers of sibutramine, a weight-loss drug.
Norton Rose Fulbright Canada LLP
Horizon Pharma PLC is seeking approval to market the drug RAVICTI (glycerol phenylbutyrate) for the treatment of urea cycle disorders.
Norton Rose Fulbright Canada LLP
Apotex Inc. (Apotex) and Apotex Pharmachem Inc. (Pharmachem) have been ordered by the Federal Court to pay to Adir and Servier Canada Inc. (collectively Servier) within 60 days a combined total of Canadian $61 million plus interest.
Field LLP
Dr. Farhat, an internationally trained pediatric radiologist, was recruited to work in Calgary. He was registered on the College's courtesy register during a fellowship.
DLA Piper
The federal Food and Drugs Act (the "FDA") establishes the main regulatory framework and provides the basic criteria for the lawful advertising of drugs in Canada.
Gowling Lafleur Henderson LLP
Justice O'Reilly of the Federal Court has rejected Teva's allegations of invalidity regarding Novartis's patent covering its iron chelator product EXJADE (deferasirox).
TTL Health Law
In 1968, the Phillip Morris Company introduced Virginia Slims, a brand of cigarette's marketed to young, professional women.
Gowling Lafleur Henderson LLP
The Regulations published are in substantially the same form as previously presented in the Notice of May 3, 2015.
Norton Rose Fulbright Canada LLP
The Federal Court issued a Notice to the Parties and the Profession dated June 24, 2015 (the "Notice") containing its initial recommendations for achieving increased proportionality in proceedings before the Court.
Norton Rose Fulbright Canada LLP
A new definition of "claim for the formulation" has been introduced.
MNP
Spring always tends to bring a renewed sense of optimism, and for the BC Wine Industry, there seems to be good reason for cautious optimism for what lies ahead during the remainder of 2015.
Norton Rose Fulbright Canada LLP
Previously announced amendments to the Patented Medicines (Notice of Compliance) Regulations (PM(NOC) Regulations) were registered and brought into force on June 19, 2015 (the Amendments).
Fuller Landau
Read the Spring/Summer 2015 edition of our Food & Beverage Newsletter.
Blake, Cassels & Graydon LLP
On June 13, 2015, the Government of Canada published proposed amendments to the Food and Drug Regulations that, if adopted, would significantly change key elements of the nutrition labelling of food products.
Torys LLP
With the Royal Assent of Québec Bill 28, the Minister of Health and Social Services (the Minister) can now enter into product listing agreements (PLAs) with pharmaceutical drug manufacturers.
Langlois Kronstrom Desjardins s.e.n.c.r.l.
The passing of Bill 28 this past April 20, within the framework of budget cuts announced by the Quebec government, has already made considerable waves, namely because of its impact on Quebec pharmacists.
Borden Ladner Gervais LLP
As all Canadian health researchers are undoubtedly aware, CIHR is in the throes of reforming the investigator-driven grants program.
Latest Video
Most Popular Recent Articles
Gowling Lafleur Henderson LLP
The employer community grapples with accommodation all the time. The task is complicated by the question of how to deal with an employee's lawful use of a product – marijuana – that is illegal in most contexts and which is perceived as recreational and hazardous.
Borden Ladner Gervais LLP
As all Canadian health researchers are undoubtedly aware, CIHR is in the throes of reforming the investigator-driven grants program.
Gowling Lafleur Henderson LLP
Medical marijuana in Canada has triggered a classic debate between those favouring its more liberal use to address medical problems, opposite those who believe greater legal access will accelerate the illegal, recreational use of cannabis.
McCarthy Tétrault LLP
Medical marijuana is becoming big business. Recently, it was announced that two titans in the medical growing sphere have agreed to merge in a $58-million deal expected to close in August.
Blake, Cassels & Graydon LLP
On June 13, 2015, the Government of Canada published proposed amendments to the Food and Drug Regulations that, if adopted, would significantly change key elements of the nutrition labelling of food products.
Norton Rose Fulbright Canada LLP
Apotex Inc. (Apotex) and Apotex Pharmachem Inc. (Pharmachem) have been ordered by the Federal Court to pay to Adir and Servier Canada Inc. (collectively Servier) within 60 days a combined total of Canadian $61 million plus interest.
McLennan Ross LLP
Last week, with its decision in Stewart v Elk Valley Coal Corporation, the Alberta Court of Appeal gave employers with safety-sensitive workplaces some additional assistance in their battle against drug and alcohol use in the workplace.
Gowling Lafleur Henderson LLP
Alternative forms of medical marijuana were legalized by the Supreme Court of Canada on June 11, 2015. The implications are significant for patients, drug producers and workplaces across the country.
Borden Ladner Gervais LLP
Canada has had, since 1993, a system linking generic drug approval to preliminary clearance of certain patent hurdles.
McCarthy Tétrault LLP
On January 7, 2015, Justice de Montigny of the Federal Court released his judgment and reasons in Eli Lilly Canada Inc. v. Mylan Pharmaceuticals ULC, 2015 FC 17.
Article Search Using Filters
Related Topics
Mondaq Advice Centre (MACs)
Popular Authors
Popular Contributors
Tools
Font Size:
Translation
Channels
Mondaq on Twitter
Partners